The short answer: yes, in narrower circumstances than before. Now that the FDA shortages are resolved, pharmacies may not routinely compound versions that are essentially copies of the approved drugs. A state-licensed 503A pharmacy may still compound a GLP-1 medication for an individual patient when a licensed prescriber determines, and documents, that a modification produces a significant clinical difference for that specific patient. The FDA's April 30, 2026 proposal would further restrict large-scale 503B compounding, with a final decision pending after the June 29 comment deadline.
Written and reviewed by Ali Claunch, NP-C · Vesta Aesthetics is a 503A-only telehealth practice serving Utah, Arizona, and Idaho
Primary sources: the FDA's April 30, 2026 announcement, the Federal Register notice, and the FDA's compounding policy statement.
Both are legal compounding pathways created by federal law, but they serve different purposes, and the 2026 changes treat them very differently.
Compounded medications are not FDA-approved and are not generics. In March 2026 the FDA warned 30 telehealth companies for exactly this kind of marketing: claiming compounded versions are the same as Wegovy, Ozempic, Mounjaro, or Zepbound, hiding which pharmacy actually makes the product, or making one-sided safety claims. Treat those claims as red flags wherever you see them.
Vesta Aesthetics is a provider-led telehealth practice, not a medication website. Every prescription begins with a private consultation with Ali Claunch, NP-C. If a compounded GLP-1 is clinically appropriate for you specifically, the prescription is patient-specific, the clinical rationale is documented, and the medication is filled by a licensed, state-inspected 503A compounding pharmacy. We tell you which pharmacy fills your prescription, we never claim a compounded medication is the same as a brand-name drug, and we monitor your progress with real follow-ups.
You can read more about our sourcing standards on The Vesta 503A Promise, or explore our medical weight loss program to see how treatment actually works.
It depends on how it is made and prescribed. Routine compounding of products that are essentially copies of the FDA-approved drugs is no longer permitted now that the shortages are resolved. A state-licensed 503A pharmacy may still compound semaglutide for an individual patient when the prescriber determines and documents that a modification, such as a clinically meaningful dose or dosage form difference, produces a significant difference for that specific patient.
The FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances. It is a proposal, not a final rule. The public comment period runs through June 29, 2026, and a final determination will follow. The proposal directly affects large-scale 503B outsourcing facilities, not patient-specific 503A pharmacies.
The FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage resolved on February 21, 2025. Enforcement discretion for compounders wound down in the months that followed, ending in spring 2025. Since then, compounded versions that are essentially copies of the commercial products may not be produced regularly or in inordinate amounts.
Under FDA guidance, a compounded drug is essentially a copy when it uses the same active ingredient in the same, similar, or easily substitutable strength, by the same route of administration as the approved product, unless the prescriber documents that a change makes a significant difference for the identified patient. The FDA has specifically cautioned that simply adding vitamin B12 to semaglutide does not automatically avoid this rule.
No. Compounded medications are not FDA-approved and are not generics, and no honest provider should tell you otherwise. Compounding is a legal, regulated practice that exists to serve individual patient needs that the commercial product does not meet. The pharmacy that compounds your medication should be licensed and state-inspected, and your prescriber should explain why a compounded option fits your specific situation.
In March 2026 the FDA warned 30 telehealth companies over illegal marketing of compounded GLP-1s. The recurring problems: claiming compounded versions are the same as Wegovy, Ozempic, Mounjaro, or Zepbound; hiding which pharmacy actually compounds the product; and making safety or effectiveness claims without fair balance. Patients should treat sameness claims and hidden sourcing as red flags.
Four questions: Which licensed pharmacy compounds my medication? Why is a compounded version clinically appropriate for me specifically? Is my prescription patient-specific and documented? And will I have real provider follow-up during treatment? If a provider cannot answer all four clearly, keep looking.
This page is educational and reflects federal regulatory status as of June 11, 2026. It is not legal advice, and it is not a substitute for an individual medical consultation. Regulations evolve; we update this page as the FDA acts. Compounded medications are not FDA-approved. Whether any treatment is appropriate for you is a decision made with a licensed provider who knows your history.
Bring them to a HIPAA compliant telehealth consultation. Straight answers, documented clinical reasoning, and a provider who will tell you if a treatment is not right for you.
Schedule a ConsultationFor Utah, Arizona & Idaho patients. Unsubscribe any time.
A Note on Compounded Medications and FDA Oversight
Compounded peptides, GLP-1 medications, hormone therapies, NAD+ preparations, and other prescription items dispensed through Vesta Aesthetics are prepared by licensed 503A compounding pharmacies for individual patients pursuant to a valid prescription from Ali Claunch, NP-C, following a personalized clinical evaluation. Compounded medications are not FDA-approved. The FDA does not evaluate compounded preparations for safety, efficacy, or potency. Vesta Aesthetics operates in compliance with FDA regulations governing 503A patient-specific compounding and does not stock, resell, or distribute medications outside this framework. If the FDA changes guidance, restricts, or removes access to any compounded preparation, Vesta will discontinue that preparation in alignment with federal regulation.
Information on this site is educational and is not a substitute for individualized medical advice, diagnosis, or treatment. Outcomes vary by patient. No specific clinical result is promised or guaranteed. Use of any prescription medication carries risk; please review all risks with your provider before beginning therapy. Vesta Aesthetics is a self-pay medical practice and does not bill insurance. See our 503A Promise for full sourcing detail.